Dr. Taylor on Findings from a Genomic Analysis on BTK Inhibitors in CLL

EP: 1.Genomic Analyses Shed Light on Mechanisms of Resistance to Noncovalent BTK Inhibitors in Relapsed/Refractory CLL

EP: 2.Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLL

Now Viewing

EP: 3.Dr. Taylor on Findings from a Genomic Analysis on BTK Inhibitors in CLL

EP: 4.Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Justin W. Taylor, MD, assistant professor, lab head/ PI, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses findings from a genomic analysis on BTK inhibitors in chronic lymphocytic leukemia (CLL).

This analysis examined a cohort of 55 patients from the phase 1/2 BRUIN study (NCT03740529) treated with pirtobrutinib (LOXO-305), Taylor says. The analysis identified 9 patients in the cohort who had resistance to the therapy, meaning most patients were still responding to pirtobrutinib, Taylor explains. However, further studies will need to be conducted to identify what the resistance in 9 patients might signal, Taylor adds.

Among the 9 patients who developed resistance, 7 of them had them had BTK mutations that were not C481S, Taylor continues. The most common mutations were L528W and T474I, which clustered within the drug binding pocket and prevented pirtobrutinib from binding, Taylor concludes